Home » Stocks » NSPR

InspireMD Inc. (NSPR)

Stock Price: $4.59 USD 0.17 (3.85%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 36.29M
Revenue (ttm) 2.46M
Net Income (ttm) -11.81M
Shares Out 7.91M
EPS (ttm) -3.98
PE Ratio n/a
Forward PE 11.70
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $4.59
Previous Close $4.42
Change ($) 0.17
Change (%) 3.85%
Day's Open 4.47
Day's Range 4.47 - 4.75
Day's Volume 163,077
52-Week Range 4.23 - 22.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

TEL AVIV, Israel, May 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of ...

1 day ago - GlobeNewsWire

TEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of...

3 days ago - GlobeNewsWire

Company Completes Up-List to Nasdaq Capital Market, with Trading Becoming Effective May 21, 2021

4 days ago - GlobeNewsWire

Ticker to remain NSPR Ticker to remain NSPR

5 days ago - GlobeNewsWire

TEL AVIV, Israel, April 29, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid ar...

2 weeks ago - GlobeNewsWire

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those...

2 weeks ago - Benzinga

InspireMD has vastly reduced the number of its shares trading ahead of a likely move to a Nasdaq listed. Conversion of NSPR stock warrants and preferred shares will be more difficult now.

Other stocks mentioned: HTBX
2 weeks ago - InvestorPlace

TEL AVIV, Israel, April 19, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke cause...

3 weeks ago - GlobeNewsWire

Penny Stocks Continue to Make Big Headway in April 2021 The post Best Penny Stocks To Buy Today? 3 Stocks To Watch In April 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...

Other stocks mentioned: ABEV, FNMA
4 weeks ago - PennyStocks

TEL AVIV, Israel, April 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke cause...

1 month ago - GlobeNewsWire

TEL AVIV, Israel, March 22, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid ar...

1 month ago - GlobeNewsWire

Management to host investor conference call today, March 9, at 8:30am ET Management to host investor conference call today, March 9, at 8:30am ET

2 months ago - GlobeNewsWire

Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET

2 months ago - GlobeNewsWire

TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery ...

2 months ago - GlobeNewsWire

TEL AVIV, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery ...

3 months ago - GlobeNewsWire

TEL AVIV, Israel, Feb. 08, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent pla...

3 months ago - GlobeNewsWire

TEL AVIV, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent pla...

3 months ago - GlobeNewsWire

New Chinese Distributor Will Also Invest in At-The-Market Private Placement New Chinese Distributor Will Also Invest in At-The-Market Private Placement

3 months ago - GlobeNewsWire

TEL AVIV, Israel, Jan. 26, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid art...

3 months ago - GlobeNewsWire

InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...

6 months ago - GlobeNewsWire

TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...

6 months ago - GlobeNewsWire

Earnings conference call to be held Monday, November 9, 2020 at 8:30 a.m. ET Earnings conference call to be held Monday, November 9, 2020 at 8:30 a.m. ET

6 months ago - GlobeNewsWire

TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid art...

7 months ago - GlobeNewsWire

TEL AVIV, Israel, Oct. 06, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by...

7 months ago - GlobeNewsWire

Advancing the CARENET-III study of CGuard System for Stroke Prevention in the United States Advancing the CARENET-III study of CGuard System for Stroke Prevention in the United States

8 months ago - GlobeNewsWire

IDE Approval to Pave the Way for Pivotal Study of CGuard System for Carotid Artery Disease and Stroke Prevention in the United States IDE Approval to Pave the Way for Pivotal Study of CGuard System for ...

8 months ago - GlobeNewsWire

TEL AVIV, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid ...

8 months ago - GlobeNewsWire

TEL AVIV, Israel, Aug. 25, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment...

8 months ago - GlobeNewsWire

TEL AVIV, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment...

9 months ago - GlobeNewsWire

InspireMD's (NSPR) CEO Marvin Slosman on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

 In the second quarter the Company was granted approval to market its CGuard™ MicroNet stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies treating pa...

9 months ago - GlobeNewsWire

Conference Call to be held Wednesday, August 5, 2020 at 8:30am ET Conference Call to be held Wednesday, August 5, 2020 at 8:30am ET

9 months ago - GlobeNewsWire

Conference Call to be held Thursday, August 5, 2020 at 8:30am ET Conference Call to be held Thursday, August 5, 2020 at 8:30am ET

9 months ago - GlobeNewsWire

In a head-to-head evaluation, significantly fewer silent brain infarcts were associated with CGuard™ EPS versus Acculink™ at 30 days post-procedure In a head-to-head evaluation, significantly fewer sile...

10 months ago - GlobeNewsWire

Results indicate that 12 months after carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained protection against postprocedural neurologic events

11 months ago - GlobeNewsWire

TEL AVIV, Israel, June 08, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid a...

11 months ago - GlobeNewsWire

TEL AVIV, Israel, June 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid a...

11 months ago - GlobeNewsWire

InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

First quarter revenue growth driven by continued strong uptake of the CGuard™ Embolic Prevention System (EPS) in the company’s major markets

1 year ago - GlobeNewsWire

InspireMD's (NSPR) CEO Marvin Slosman on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Case demonstrates ease-of-use and exceptional patient safety features of CGuard™ EPS Case demonstrates ease-of-use and exceptional patient safety features of CGuard™ EPS

1 year ago - GlobeNewsWire

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Other stocks mentioned: CVEO, GCO, RDWR, WPRT
1 year ago - Zacks Investment Research

InspireMD, Inc. (NSPR) CEO Jim Barry on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

TEL AVIV, Israel, Sept. 19, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid ...

1 year ago - GlobeNewsWire

TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid ...

1 year ago - GlobeNewsWire

TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid arte...

1 year ago - GlobeNewsWire

InspireMD, Inc. (NSPR) CEO Jim Barry on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

InspireMD (NSPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

InspireMD, Inc. (NSPR) CEO Jim Barry on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About NSPR

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing ... [Read more...]

Industry
Medical Devices
CEO
Marvin Slosman
Employees
45
Stock Exchange
NYSEAMERICAN
Ticker Symbol
NSPR
Full Company Profile

Financial Performance

In 2020, InspireMD's revenue was $2.49 million, a decrease of -33.22% compared to the previous year's $3.72 million. Losses were -$10.54 million, 5.02% more than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for InspireMD stock is "Buy." The 12-month stock price forecast is 15.75, which is an increase of 243.14% from the latest price.

Price Target
$15.75
(243.14% upside)
Analyst Consensus: Buy